The United States Pharmacopeia (USP) has announced its intention to revise the Sennosides Tablets monograph testing method. This proposed change, initiated by the Botanical Dietary Supplements and Herbal Medicines Expert Committee, will align the specific monograph's testing procedure with the recently updated general sennosides monograph. The revision will adopt the use of sennosides A and B as marker compounds for strength and incorporate the requirement for determining other minor sennosides in standardized ratios, as already defined in the Identification test.

This revision is anticipated to be published as an In-Process Revision in a future Pharmacopeial Forum. While this notice itself does not impose immediate compliance obligations, manufacturers relying on the Sennosides Tablets monograph should monitor the Pharmacopeial Forum for the proposed revision and prepare to implement the updated testing method by the targeted official date of August 1, 2027. The USP provides contact information for questions regarding this revision.